Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)
Atrial Fibrillation, Inflammation
About this trial
This is an interventional prevention trial for Atrial Fibrillation focused on measuring Reactive Oxgen Speers, Atrial Fibrillation, Oxidative Stress, Inflammation
Eligibility Criteria
Inclusion Criteria: > or = 18 years of age Clinical diagnosis-abnormal heart beat known as atrial fibrillation/flutter (ECG documentation) Able to swallow pill form of drug Exclusion Criteria: < 18 years of age enrollment in another ongoing trial paroxysmal atrial fibrillation hemodynamic instability atrial fibrillation ablation within 6 months of enrollment a contraindication for anticoagulation severe valvular heart disease presence of single lead implantable cardioverter defibrillator unstable angina New York Heart Association (NYHA) Class IV heart failure hyperthyroidism uncontrolled hypertension (blood pressure > 180/100 at rest) on medications an illness that would limit life expectancy to less than 1 year use of statins within the previous 30 days significant coronary artery disease or lipid abnormalities necessitating statin therapy implanted devices for active management of arrhythmias by pacing or defibrillation lack of access to a telephone illicit drug use alcohol abuse hypersensitivity to atorvastatin by history pregnancy sexually active female subjects not on contraception or surgically sterilized nursing mothers chronic liver disease or abnormal liver function (elevated transaminases 1.5 times the upper limit of normal [ULN] of laboratory reference range) severe renal disease (creatinine > 200 mmol/L) inflammatory muscle disease or creatine kinase (CK) > 3 times ULN concurrent treatment with cyclosporine, fibrates, or high-dose niacin
Sites / Locations
- Veteran Administration Medical Center/Emory University
- Crawford Long Hospital
- The Emory Clinic
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
Placebo
Atorvastatin
Placebo taken daily
Atorvastatin at a dose of 80 mg daily